Astrana Health, Inc. reported nine-month revenue of $2,961.2 million, up 33%, and attributable net income of $47.1 million, up $30.6 million. The full impact of the cybersecurity incident remains unquantified.
ASTH · Astrana Health, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $28.68
- Open
- $29.49
- Day range
- $27.98–30.31
- 52-week closing range
- $18.16–49.81
- Average volume, 30 days
- 361K
- Short interest
- 3.0M · 5.4% of shares · 12.3 days
- Short volume, last session
- 58%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 6
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Astrana delivered record third-quarter revenue of $1.02 billion and adjusted EBITDA of $77.2 million, up 7% and 13%, respectively. It maintained full-year revenue guidance of $3.9 billion to $4 billion and adjusted EBITDA guidance of $261 million to $274 million.
Astrana Health reported third-quarter revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million and adjusted EBITDA of $77.2 million, up 13%.
Astrana Health updated its corporate presentation on September 23, 2026, raising FY2026 Adjusted EBITDA guidance to $255 – $280M and reaffirming revenue guidance of $3,800 – $4,100M and free cash flow guidance of $105 – $132.5M.
Astrana Health, Inc. deemed a social-engineering incident material on September 22, 2026; it believes private or confidential information may have been accessed, but cannot estimate impact and does not expect a material effect on financial condition or results of operations.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Astrana delivered record third-quarter revenue and adjusted EBITDA, with organic earnings growth, favorable medical-cost performance, expanding full-risk exposure, new partnerships and strong cash generation and deleveraging. The main risks are Medicaid attrition, trend pressure and 2027 headwinds, along with a lower-profitability fourth quarter, an unresolved cyber incident and continued remediation of a material weakness.
- + Third-quarter revenue reached a record $1,023.6 million, up 7% year-over-year, while adjusted EBITDA reached a record $77.2 million, up 13%.
- + Adjusted EBITDA growth was organic, driven by cohort maturation, improved medical-cost performance and operating efficiencies.
- + The company expects approximately 82% of capitation revenue to be generated under full-risk arrangements by year-end, up from 76% at year-end 2025.
- + Astrana expanded its footprint through a Georgia acquisition, two care-enablement clients and several new Medicare Advantage payer partnerships effective January 1, 2027.
- + Consolidated medical-cost trend year to date is slightly better than the approximately 5.2% assumption embedded in full-year guidance.
- + The company generated approximately $105 million of free cash flow through the first nine months and reduced trailing net leverage to approximately 2.2 times.
- − Medicaid attrition is expected to be at the middle-to-high-end of the original 10% to 15% assumption.
- − Management expects a mid-single-digit net EBITDA-growth headwind from Medicaid and a 10% to 15% membership decline in 2027.
- − Medicaid medical-cost trend is above initial expectations, and management is beginning to see adverse selection among remaining members.
- − Management expects the fourth quarter to be the year's lowest quarter in terms of profitability.
- − A cyber incident involving criminal activity remains under investigation with law enforcement.
- − The company is still remediating a previously disclosed material weakness in internal control over financial reporting.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $212.4M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 7% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted EPS - diluted non-GAAP | $2.25 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted net income attributable to Astrana Health, Inc. non-GAAP | 111.35M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Annual Wellness Visit (AWV) program reach of eligible members | 65% | Year to date 2026 | — |
| EBITDA non-GAAP | 159.04M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $105.4M | nine months ended September 30, 2026 | — |
| G&A expense | 6.2% | Year-to-date 2026 | — |
| members in our Care Partners segment | 1.2M | Third Quarter 2026 | — |
|
|
|||
| patients in value-based arrangements | 1.5M | Third Quarter 2026 | — |
|
|
|||
| YTD Free Cash Flow non-GAAP | $105.45M | nine months ended September 30, 2026 | — |
| Q2 2026 capitation revenue from full-risk arrangements | 81% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASTH
this stock
Astrana Health, Inc.
|
$1.60B | +15.6% | +45.9% | 26.8 | 5.4% |
|
HCA
HCA Healthcare, Inc.
|
$96.16B | -1.4% | +7.1% | 15.3 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$32.17B | -0.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.98B | +32.6% | +0.9% | 7.6 | 2.2% |
|
EHC
Encompass Health Corp
|
$12.98B | +24.6% | +10.5% | 20.7 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 28
Astrana Health, Inc. reported nine-month revenue of $2,961.2 million, up 33%, and attributable net income of $47.1 million, up $30.6 million. The full impact of the cybersecurity incident remains unquantified.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASTH | -9.7% | -24.6% | -24.1% | -21.5% | +15.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -4.3% | -18.3% | -18.4% | -16.2% | +10.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.